002864
vs
S
Shanghai Composite
002864
Over the past 12 months, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd has outperformed Shanghai Composite, delivering a return of +26% compared to the Shanghai Composite's +23% growth.
Stocks Performance
002864 vs Shanghai Composite
Performance Gap
002864 vs Shanghai Composite
Performance By Year
002864 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd
Glance View
Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd. engages in the GAP planting of medicinal materials, drug production, research and development, sales and medical logistics. The company is headquartered in Xi'An, Shaanxi and currently employs 901 full-time employees. The company went IPO on 2017-11-16. The firm's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The firm also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The firm is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The firm distributes its products within domestic market.
